The vast majority1 of Canadian patents currently in force carry a term limited to twenty years from the filing date. However, as part of Canada’s obligations under CETA2 certain patents relating to drugs authorized for human or veterinary use now qualify for up to two additional years of protection3 through a Certificate of Supplementary Protection (CSP). This article provides a brief overview of this new form of patent term extension including what patents are eligible, timing considerations and the requirements for an application.

Eligible Patents

To be eligible for a CSP, the patent must be in force and have issued from an application filed on or after October 1, 1989. The patent must also pertain to a medicinal ingredient or a combination of medicinal ingredients contained in a drug for which a notice of compliance (marketing authorization) has issued on or after September 21, 2017.

A patent pertains to a medicinal ingredient or combination thereof if it contains a claim for:

(a) the medicinal ingredient or combination of all the medicinal ingredients;

(b) the medicinal ingredient or combination of all the medicinal ingredients as obtained by a specified process; or

(c) a use of the medicinal ingredient or combination of all the medicinal ingredients,

contained in the drug for which the notice of compliance issued. Claims that are directed to formulations comprising a medicinal ingredient in combination with other elements are not eligible for a CSP.4 Uses of such formulations are also likely not eligible for a CSP. This reflects the language of CETA which refers to patents that protect “a product as such”.5 The claimed use does not need to match the use approved in the notice of compliance; it merely needs to include use in humans or animals, as the case may be.6

The notice of compliance must be the first that has been issued with respect to a medicinal ingredient or combination thereof. Additionally, there may only be one CSP issued in respect of a medicinal ingredient or combination thereof.7 The CSP Regulations8 set out a number of variations in structure of a particular medicinal ingredient which would result in a finding that they are the same medicinal ingredient.9 In addition, for the purposes of CSPs, if combinations vary only with respect to the ratio between the medicinal ingredients, they are treated as the same combination. However, if a medical ingredient or combination of medicinal ingredients contained in a drug is authorized for both human and veterinary use, these are treated as different medicinal ingredients or combinations.

Timing Considerations

To be eligible for a CSP, the application for marketing approval in Canada must have been made within a certain period from the time the first marketing approval was submitted in any one of the following countries/regions: the European Union (and any country that is a member of the European Union), the United States, Australia, Switzerland and Japan. If the CSP application is filed up until September 21, 2018 the period of time is 24 months. After this day, the period of time will be 12 months.

If the patent was already granted at the time the notice of compliance issues, the CSP application must be filed within 120 days from the day on which the notice of compliance issued. If the patent application is still pending at the time the notice of compliance issues, the CSP application must be filed within 120 days from the time the patent is granted.

Application Formalities

The contents of the CSP application are not onerous. The application requires two forms; the “Certificate of Supplementary Protection (CSP) Application Form” and the “Advance Payment Details for Drug Submissions and Master Files for Human and Disinfectant Drugs, and Certificate of Supplementary Protection Applications Form” and paying the required fee. The information needed for these forms is generally clerical in nature.

The application fee for a CSP was initially CDN $9,011. Beginning on April 1, 2018, the fee increased annually by 2% of the fee payable in the previous year, rounded up to the nearest dollar. This means the fee is currently CDN $9192.

Outlook

According to the register maintained by Health Canada, eighteen applications for CSPs have now been filed for human use and one has been filed for veterinary use. Of the applications, twelve have issued, four are still pending and only three have been rejected. All of the CSPs which have issued to date are for the maximum term of two years.

Patentees interested in seeking CSP protection for a patent relating to a drug should be mindful of the important timing requirements both in respect of the filing of applications for marketing approval and the CSP application itself. Patentees should also be aware that the subject-matter eligible for a CSP does not completely overlap with that eligible for listing on Health Canada’s Patent Register. Accordingly, if there is interest down the line in seeking a CSP for a patent application that is still pending at the Canadian Patent Office, patentees may wish to consult with their agent to ensure, where possible, claims are included that fit within the above-discussed categories of eligible subject-matter. To this end, because CSPs only recently became available in Canada, it will be some time before we receive any interpretation from the courts regarding these provisions. In the interim, Health Canada has provided some guidance on its interpretation of subject-matter eligibility, including assessment of variations between medicinal ingredients.